[{"id":"pyrotinib","kind":"drug","name":"Pyrotinib","route":"/drugs/pyrotinib/","commit":"ad64caf371","date":"2026-09-10","author":"Jude Gomila","message":"Primary source links (FDA label via DailyMed) for a fifth batch of approved products","file":"src/data/spikes/breast-her2-positive.ts","type":"changed","fields":[{"field":"links","after":"[{ label: \"FDA label (DailyMed)\", url: \"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Pyrotinib\" }]"}]},{"id":"pyrotinib","kind":"drug","name":"Pyrotinib","route":"/drugs/pyrotinib/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/spikes/breast-her2-positive.ts","type":"changed","fields":[{"field":"tldr","before":"\"China's HER2 pill, widely used there with capecitabine and as a comparator for the new Chinese HER2 ADCs.\"","after":"\"Pyrotinib is China's HER2 pill, widely used there with capecitabine and as a comparator for the new Chinese HER2 ADCs.\""},{"field":"summary","before":"\"Jiangsu Hengrui. PHOEBE (vs lapatinib + capecitabine): PFS 12.5 vs 6.8 months; PHILA (first-line with trastuzumab + docetaxel): PFS 24.3 vs 10.4 months. Approved in China (2018, 2020s expansions); not approved in the...","after":"\"Pyrotinib is Jiangsu Hengrui's HER2 TKI. PHOEBE (vs lapatinib + capecitabine): PFS 12.5 vs 6.8 months; PHILA (first-line with trastuzumab + docetaxel): PFS 24.3 vs 10.4 months. Approved in China (2018, 2020s expansio..."}]},{"id":"pyrotinib","kind":"drug","name":"Pyrotinib","route":"/drugs/pyrotinib/","commit":"f8e98e6f47","date":"2026-09-08","author":"Jude Gomila","message":"Spikes: HR+/HER2- and HER2+ breast cancer to TNBC depth (structured trial outcomes, dosing, toxicity, regulatory events)","file":"src/data/spikes/breast-her2-positive.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"brand"},{"field":"modality"},{"field":"status"},{"field":"tldr"},{"field":"summary"},{"field":"mechanism"},{"field":"dosing"},{"field":"toxicity"},{"field":"approvals"},{"field":"targets"},{"field":"technologies"},{"field":"companies"},{"field":"cancers"},{"field":"trials"}]}]